Entries |
Document | Title | Date |
20100261646 | SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES - Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (TOP) in the eye. In one embodiment, the microspheres are formed from polylactide-co-glycolide (“PLGA”); in another embodiment, the microspheres are formed from a blend PLGA and poly lactic acid (“PLA”). Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time. The combination of drug loading and release rate, as well as the minimization of initial burst release, result in prolonged release of a higher amount of drug. | 10-14-2010 |
20100273705 | Method for inhibiting "Melanoma Inhibitory Activity" MIA - The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA). | 10-28-2010 |
20100279933 | VEGF ANTAGONIST FORMULATIONS - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 11-04-2010 |
20100286038 | FORMULATION CONTAINING CYCLIN-DEPENDENT KINASE INHIBITING COMPOUND AND METHOD OF TREATING TUMORS USING THE SAME - This application discloses a novel formulation containing a 3-amino-4-substituted pyrazole derivative which has cyclin-dependent kinase inhibiting properties, and a method of treating tumors using the novel formulation. | 11-11-2010 |
20100286039 | Use of SCF and G-CSF in the Treatment of Cerebral Ischemia and Neurological Disorders - The present invention relates to the use of stem cell factor (SCF) polypeptide, alone and in combination with granulocyte colony stimulating factor (G-CSF) polypeptide, in the prevention or treatment of injury to the brain after cerebral ischemia or neurological disorder. More particularly, the invention provides methods of improving neurological function and outcome after stroke by the administration of SCF polypeptide, alone and in combination with G-CSF polypeptide. This treatment can be used alone or in combination with other well-known methods of treatment of cerebral ischemia and neurological disorders in a mammal. | 11-11-2010 |
20100286040 | PRO-ANGIOGENIC PEPTIDES AND USES THEREOF - This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject. | 11-11-2010 |
20100298218 | Single Branch Heparin-Binding Growth Factor Analogs - A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same. | 11-25-2010 |
20100317577 | Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation - The present invention provides compositions and methods that enhance cell survival. Such compositions feature chimeric polypeptides that include at least a GM-CSF receptor ligand and an anti-apoptotic moiety (e.g., a Bcl-2 protein family member). In one embodiment, the chimeric polypeptide is a GM-CSF-Bcl-xL chimeric polypeptide. The invention further includes methods of using chimeric polypeptides to enhance cell survival or inhibit cell death in a cell at risk of cell death. | 12-16-2010 |
20100323958 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial - This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body. | 12-23-2010 |
20100323959 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial - This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body. | 12-23-2010 |
20100323960 | Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial - This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body. | 12-23-2010 |
20100323961 | SURFACE ERODING SUTURES - Barbed surgical sutures comprised of surface eroding materials are provided having increased degradation rates are provided. | 12-23-2010 |
20100331249 | Pharmaceutical composition for inhibiting peritoneal dissemination - A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and an acceptable receptor thereof. | 12-30-2010 |
20110003742 | Naphthalimide Dosing by N-Acetyl Transferase Genotyping - The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combination with naphthalimide to prevent or modulate leukocytopenia. | 01-06-2011 |
20110003743 | STEM CELL DERIVED FACTORS FOR TREATING PATHOLOGIC CONDITIONS - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions. | 01-06-2011 |
20110015125 | ADHESIVES AND METHODS OF APPLYING THE SAME - A composition including pre-gel including at least one phenol-based compound, excluding phloroglucinol and derivatives, at least one water miscible polymer, at least one cross linking agent capable of interacting with the polymer. The polymer is selected from one or more natural and/or synthetic carbohydrate, and salt of an anionic polysaccharide. | 01-20-2011 |
20110034381 | Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH) - Therapeutic methods for treatment of benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I). Methods encompass the use of IGF-I antagonists, as well as the use of compounds that lower the effective level of IGF-I or interfere with post receptor effects of IGF-I action in the prostate. | 02-10-2011 |
20110034382 | USE OF LIVER GROWTH FACTOR (LGF) AS A NEURAL TISSUE REGENERATOR - The invention comprises the use of LGF in the production of medicinal products that can be used in the pleiotropic tissue regeneration of one or more damaged tissues, in which at least one of the damaged tissues forms part of the central nervous system and the medicinal product is intended to be administered systemically. The invention is based on the fact that intraperitoneal administration of LGF can promote a positive effect on a Parkinson's disease model. As such, in a preferred embodiment of the invention, the medicinal product is intended for the treatment of Parkinson's disease, particularly when the medicinal product is intended for humans. | 02-10-2011 |
20110046057 | USES OF CERBERUS AND DERIVATIVES THEREOF - The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. | 02-24-2011 |
20110092420 | SELENIUM CONTAINING MODIFYING AGENTS AND CONJUGATES - The invention relates to a modifying agent comprising a water soluble polymer, wherein the water soluble polymer comprises at least one reactive selenium group, said reactive selenium group being capable of reacting with a thiol group thereby forming an —Se—S— bond. Furthermore, the invention relates to a method for producing said modifying agents and their use in the modification of pharmaceutically active agents, e.g. G-CSF. Additionally, the invention concerns conjugates comprising a water-soluble polymer and a pharmaceutically active agent, wherein the water-soluble polymer is linked via a S—Se-bond to agent and a method for their production and their use as medicaments. Finally, the invention concerns a pharmaceutical composition comprising the inventive conjugates. | 04-21-2011 |
20110190203 | Ophthalmic Compositions Containing A Synergistic Combination Of Two Polymers - Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity. | 08-04-2011 |
20110245168 | CONTROL OF GROWTH AND REPAIR OF GASTRO-INTESTINAL TISSUES BY GASTROKINES AND INHIBITORS - A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers. | 10-06-2011 |
20110275563 | Use of CTGF as a Cardioprotectant - The present invention is based upon the surprising discovery that Connective Tissue Growth Factor (CTGF) may act directly on the heart as a cardioprotective factor and provides CTGF for use in the treatment of a subject who has incurred or is incurring damage to the heart, wherein said CTGF is for administration during or after the heart-damaging event. The invention also relates to CTGF for use in protection of the heart during or after surgery or during ex vivo transportation or storage of an explanted heart. | 11-10-2011 |
20110294731 | SKIN CREAM - Preferred embodiments of the invention relate to compositions, including anti-aging cosmeceuticals for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture. | 12-01-2011 |
20110306545 | NOVEL PEPTIDES FOR WOUND HEALING - The present invention relates to new peptides, pharmaceutical composition and cosmetic composition including them and their use for wound healing. | 12-15-2011 |
20110312884 | Noggin-Derived Peptide and Use Thereof - Disclosed are a noggin-derived peptide and a composition containing the same for promoting hair growth, improving skin conditions, providing anti-inflammatory function, or preventing or treating bone diseases. The disclosed noggin-derived peptide performs a function identical or similar to that of natural human noggin and is superior in stability and skin permeability as compared thereto. The composition containing the peptide of the present disclosure as an active ingredient exhibits remarkably superior effects in treating, preventing or improving growth factor-related symptoms, e.g. hair loss, skin conditions or cut, or treating, preventing or improving growth factor overexpression-related symptoms. Therefore, the superior activity and stability of the peptide of the present disclosure are greatly advantageous in application to medicine, quasi-drugs and cosmetics. | 12-22-2011 |
20110312885 | CONTROLLED RELEASE SYSTEM AND MANUFACTURING METHOD THEREOF - A controlled release system and manufacturing method is provided. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere. | 12-22-2011 |
20120004169 | MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS - The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity. | 01-05-2012 |
20120015877 | USE OF GDF TRAPS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 01-19-2012 |
20120077740 | Methods for making Apo-2 Ligand using divalent metal ions - Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis. | 03-29-2012 |
20120108509 | ARTIFICIAL SCAB FOR USE IN AN AIRWAY - Body tissue and structures in an airway may be treated with an artificial scab comprising an inhomogeneous, uncohesive, solid sheet-like body comprising a granular mixture of chitosan and polysaccharide particles. The artificial scab breaks apart into smaller pieces if peeled away from the surgical site or wound, thus reducing the risk of airway occlusion. | 05-03-2012 |
20120135924 | Prosthesis for Joint Cartilage Repair and Method of Manufacture - A cartilage prosthesis is made according to a method that includes the steps of collecting animal material from a bovine, ovine or porcine source, the animal material being a cartilage, shaping the animal material to provide a desired shape for the cartilage implant, removing cells from the animal material, crosslinking the animal material, removing antigens from the animal material, subjecting the animal material to an alkaline treatment, coupling into the animal material active substances which are capable of adhering growth factor and stem cell, and packing the animal material in a container that contains a sterilization solution. | 05-31-2012 |
20120135925 | Covalent Inhibition of Bacterial Quorum Sensing - Inhibitors of bacterial communication, such as quorum sensing, and method of use and manufacture thereof. | 05-31-2012 |
20120165253 | PHARMACEUTICAL COMPOSITION FOR INHIBITING PERITONEAL DISSEMINATION - A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and an acceptable receptor thereof. | 06-28-2012 |
20120165254 | SULPHATED HYALURONIC ACID FOR TREATING DEGENERATIVE OSTEOARTHRITIS - This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis. | 06-28-2012 |
20120165255 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD FOR PERIODONTAL DISEASES AND PULPAL DISEASES - The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue.
| 06-28-2012 |
20120190619 | METHODS OF IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS - A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing WIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the FcγRIIB receptor and in turn inhibiting a cellular-mediated inflammatory response. | 07-26-2012 |
20120196803 | FUSION PROTEINS FOR DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM - The present invention relates to a compound that includes a peptide vector, such as angiopep-2 which acts as a carrier across the blood-brain barrier, linked to glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), or a related molecule, such as an analog or a fragment thereof. The compounds of the invention may be used to treat any disease where increased neuronal survival or growth is desired, e.g., neurodegenerative diseases, such as Parkinson's disease or amyotrophic lateral sclerosis. Other diseases can be treated using the compounds include schizophrenia and depression. | 08-02-2012 |
20120202740 | SCGB3A2 AS A GROWTH FACTOR AND ANTI-APOPTOTIC AGENT - The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents. | 08-09-2012 |
20120208752 | CELL PROLIFERATION-PROMOTING PEPTIDE AND USE THEREOF - A cell proliferation promoter includes, as an active ingredient, an artificially synthesized peptide that includes (A) an amino acid sequence constituting a membrane-permeable peptide and (B) an amino acid sequence selected from SEQ ID NOs: 19 to 103 or an amino acid sequence formed by substituting, deleting and/or adding one or several amino acid residues in the selected amino acid sequence. | 08-16-2012 |
20120225814 | HYDROGEL-BASED VASCULAR LINEAGE CELL GROWTH MEDIA AND USES THEREOF - A medium for growing vascular lineage cells is described. The vascular lineage cell growth medium includes an oligosaccharide-based hydrogel and a growth factor that promotes vascularization by vascular lineage cells. | 09-06-2012 |
20120232006 | PRODUCTION OF POLYURETHANE FOAMS - The invention relates to a process for producing polyurethane foams, by frothing and drying mixtures of specific polyurethane dispersions and crosslinkers. | 09-13-2012 |
20120283183 | METHOD OF REDUCING CELL DEATH BY ADMINISTERING A PARACRINE FACTOR OF A MESENCHYMAL STEM CELL - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions. | 11-08-2012 |
20120309678 | Treatment of Inflammatory Bowel Diseases With Mammal Beta Defensins - The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins. | 12-06-2012 |
20120316109 | POLYMER-CONJUGATED GLYCOSYLATED NEUBLASTIN - The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin. | 12-13-2012 |
20120322729 | HIGH ACTIVITY GROWTH FACTOR MUTANTS - The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity. | 12-20-2012 |
20130023473 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITY - The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction. | 01-24-2013 |
20130029907 | Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof - The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX | 01-31-2013 |
20130029908 | CERBERUS/COCO DERIVATIVES AND USES THEREOF - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives. | 01-31-2013 |
20130040879 | Methods For Treating Congestive Heart Failure - The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene. | 02-14-2013 |
20130045917 | METHOD OF SELECTING POLYPEPTIDE SEQUENCE, AND METAL OXIDE OR SILICON-CONTAINING COMPOUND BINDING PEPTIDE AND USE THEREOF - Provided is a peptide including the following amino acid sequence. Tyr-Xaa | 02-21-2013 |
20130053313 | NEW FORMULATION FOR INCREASING BIOAVAILABILITY OF NEURTURIN - The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability. | 02-28-2013 |
20130072429 | ASSAYS AND METHODS USING BIOMARKERS - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided. | 03-21-2013 |
20130109623 | G-CSF AND WATER-SOLUBLE POLYMER CONJUGATE | 05-02-2013 |
20130130978 | METHOD OF TREATING ENDOTHELIAL DYSFUNCTION - Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders. | 05-23-2013 |
20130143805 | GGF2 AND METHODS OF USE - Provided herein are methods of treating central nervous system injury (e.g., spinal cord injury) using GGF2 and compositions comprising GGF2. For example, provided is a method of treating spinal cord injury in a subject, comprising administering at least one dosage of less than 1 mg/kg of GGF2 to the subject. Also provided are methods of promoting proliferation of neural stem cells and of promoting revascularization comprising using GGF2 and compositions comprising GGF2. | 06-06-2013 |
20130157944 | Treatment of Myocardial Infarction and Vascular Injury with Netrin-1 - Disclosed herein are methods for treating, inhibiting, or reducing ischemia/reperfusion injury of a cardiac tissue; increasing phosphorylation of ERK1/2 and/or eNOS in a cardiac tissue; treating, inhibiting, or reducing loss of NO; treating, inhibiting, or reducing uncoupling of NOS; increasing recoupling of NOS; treating, inhibiting, or reducing loss of DCC protein and mRNA expression in a cardiac tissue; decreasing or reducing the infarct size of a heart resulting from ischemia/reperfusion injury; decreasing or reducing superoxide production by a cardiac tissue caused by ischemia/reperfusion injury; treating, inhibiting, or reducing neointimal formation and restenosis; treating, inhibiting, or reducing apoptosis of mobilized endothelial progenitor cells; or a combination thereof of a blood vessel (such as an artery, a coronary artery, a vein, or a capillary) or a portion of the blood vessel in a subject which comprise the administration of netrin-1. | 06-20-2013 |
20130157945 | PEPTIDES TARGETING TNF FAMILY RECEPTORS AND ANTAGONIZING TNF ACTION, COMPOSITIONS, METHODS AND USES THEREOF - The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided. | 06-20-2013 |
20130172251 | MODIFIED GHRELIN PEPTIDES - The present invention provides a novel peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof. | 07-04-2013 |
20130190234 | THE USE OF ALKYLATED SEMI-SYNTHETIC GLYCOSAMINOGLYCOSAN ETHERS FOR THE TREATMENT OF DENTAL DISORDERS - Described herein are methods for treating a dental disorder in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C | 07-25-2013 |
20130203667 | Methods and Compositions for Promoting Organ Development - Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof. | 08-08-2013 |
20130210723 | Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage - The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium. | 08-15-2013 |
20130231283 | NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE - The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability. | 09-05-2013 |
20130288962 | METHODS AND COMPOSITIONS FOR THE REPAIR AND/OR REGENERATION OF DAMAGED MYOCARDIUM - Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration cytokines are disclosed and claimed. Methods and compositions for the development of large arteries and vessels are also disclosed and claimed. The present application also discloses and claims methods and media for the growth, expansion, and activation of human cardiac stem cells. | 10-31-2013 |
20130316947 | THERAPEUTIC USE OF SCGB3A2 - The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents. | 11-28-2013 |
20130316948 | GROWTH HORMONE RECEPTOR DEFICIENCY CAUSES A MAJOR REDUCTION IN PRO-AGING SIGNALING, CANCER AND DIABETES IN HUMANS - A method for alleviating a symptom of chemotherapy in a subject comprises identifying a subject undergoing chemotherapy and then administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject. Typically, the levels of IGF-1 and/or GH in the subject are monitored as well as chemotherapy related symptoms. A method of alleviating oxidative damage, cellular damage including mutations, and insulin resistance in a subject is also provided. | 11-28-2013 |
20130338069 | Preparation of a Therapeutic Composition - A pharmaceutical composition includes a peptide nucleotide composition including Peptide A and Peptide B. Peptide A may be characterized by having SEQ. ID NO: 1. Peptide A may also be characterized by including 31 amino acids lacking any cysteine-cysteine cross links and including six spaced-out proline residues and four glutamine residues. Peptide B may be characterized by having SEQ. ID NO: 2. Peptide B may also be characterized by including 21 amino acids attached at a seine residue in position 18 to a diadenine (3′-5′) diribonecleotide through a diphosphodiester linkage at the 3′-position. | 12-19-2013 |
20130345130 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEART FAILURE AND METHOD FOR SCREENING AGENT FOR PREVENTING OR TREATING HEART FAILURE - The present invention relates to a pharmaceutical composition for preventing or treating a heart failure and a method for screening a therapeutic agent for preventing or treating a heart failure. The pharmaceutical composition of the present disclosure comprises the CCN5 or CCN2ΔCT protein, or a genetic carrier comprising a nucleotide sequence encoding the CCN5 or the CCN2ΔCT protein, exhibiting dramatic prevention or treatment efficacies on a heart failure even without surgical treatments accompanied with transplanting a donor heart. | 12-26-2013 |
20130345131 | Method for Achieving Desired Glial Growth Factor 2 Plasma Levels - The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient. | 12-26-2013 |
20140031283 | ANTICANCER FUSION PROTEIN - A fusion protein comprising domain (a) which is the functional fragment of a hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and at least one domain (b) which is the sequence of an effector peptide having anti-proliferative activity against tumour cells, wherein the sequence of domain (b) is attached at the C-terminus or at the N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases. | 01-30-2014 |
20140073566 | METHODS OF USING CHIMERIC COILED-COIL MOLECULE - The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand. | 03-13-2014 |
20140088007 | COMPOSITION FOR THE ATTACHMENT OF IMPLANTS TO COLLAGEN OR OTHER COMPONENTS OF BIOLOGICAL TISSUE - The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation. The invention also relates to the use and manufacture of this novel composition, as well as a novel use for the protein CNA. | 03-27-2014 |
20140088008 | NOVEL ACTIVIN RECEPTOR AND USES THEREOF - The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided. | 03-27-2014 |
20140113858 | PEPTIDE FOR INHIBITION OF BINDING BETWEEN ANGIOPOIETIN-2 AND INTEGRIN AND USE THEREOF - There are provided an angiopoietin-2 (Ang2) derived peptides, polypeptides, and peptide complexes, and a method for inhibition of binding between Ang2 and integrin and prevention and/or treatment of a disease caused by the activation of Ang2 or the binding between Ang2 and integrin using the peptide, polypeptides, and peptide complexes. | 04-24-2014 |
20140113859 | USE OF LIVER GROWTH FACTOR (LGF) AS A NEURAL TISSUE REGENERATOR - A method of treating neurodegenerative diseases, such as Alzheimer's disease, with LGF administered systemically. | 04-24-2014 |
20140162950 | METHOD FOR INHIBITING PERITONEAL METASTASIS CAUSED BY GASTRIC CANCER CELLS - The present invention provides a method for inhibiting peritoneal metastasis caused by gastric cancer cells in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of a connective tissue growth factor (CTGF), wherein the CTGF binds to an integrin α3β1 of the gastric cancer cells. The present invention also provides a method for predicting peritoneal metastasis caused by gastric cancer cells in a subject comprising providing a peritoneal tissue from the subject; measuring a first expression amount of a connective tissue growth factor (CTGF) from the peritoneal tissue; and comparing the first expression amount to a reference expression amount of the CTGF from a non-peritoneal metastasis gastric cancer tissue. | 06-12-2014 |
20140187485 | NOVEL RECEPTOR NUCLEIC ACIDS AND POLYPEPTIDES - Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided. | 07-03-2014 |
20140200179 | WNT COMPOSITIONS AND METHODS OF USE THEREOF - Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as “mini-wnts”. These compositions and methods find particular use in determining bind to Wnt receptors; inhibiting Wnt signaling in a cell that expresses a Wnt receptor; in delivering a functional moiety to a cell that expresses a Wnt receptor; and as an immunogen for producing Wnt-specific antibodies. | 07-17-2014 |
20140256627 | METHODS OF DELIVERING PHARMACEUTICAL AGENTS - Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject. | 09-11-2014 |
20140256628 | Compositions And Methods For Treating Glioma - Isolated peptides, compositions and methods of use for treating tumors infiltrated with macrophages, such as glioblastomas. | 09-11-2014 |
20140274893 | Methods and Acellular Compositions For Treating Inflammatory Disorders - Acellular compositions for treating inflammation, comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. Components of the acellular compositions may be derived from biologic materials, such as blood clots and urine. Components may also be obtained from cell cultures. | 09-18-2014 |
20140274894 | METHODS FOR MAKING CYTOKINE COMPOSITIONS FROM TISSUES USING NON-CENTRIFUGAL METHODS - Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in IL-1ra can also include at least one of sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1 RII. | 09-18-2014 |
20140274895 | Methods And Non-Immunogenic Compositions For Treating Inflammatory Disorders - Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII, Compositions may also contain white blood cells and platelets. | 09-18-2014 |
20140287995 | STABLE PHARMACEUTICAL FORMULATIONS OF GROWTH FACTOR PEPTIDES - The present disclosure provides pharmaceutical formulations including a kidney growth factor peptide and one or more excipients, wherein the formulations have a pH of greater than about 6.8. The disclosure also provides processes for preparing the formulation and products prepared by such processes. | 09-25-2014 |
20140323400 | USE OF FIBROMODULIN AND LUMICAN FOR INCREASING MUSCLE MASS - The invention relates to the use of fibromodulin and lumican, particularly active fragments thereof, to increase muscle mass, especially in the treatment of muscular dystrophies. | 10-30-2014 |
20140371143 | NEW PEPTIDE INHIBITING RANKL-RANK INTERACTION AND THE USE THEREOF - Provided are a peptide for inhibiting an interaction between an RANKL and an RANK consisting of an amino acid sequence of SEQ ID NO: 1 and a pharmaceutical composition for preventing or treating bone diseases including the peptide. The peptide consisting of an amino acid sequence of SEQ ID NO: 1 is not present in a cyclic shape, and has 10 or less amino acids, thereby having better biostability than a conventional peptide to inhibit an RANKL-RANK interaction, being preferable in price during synthesis, and having a better RANKL-RANK interaction inhibitory effect. For this reason, the peptide may be used as an effective component of the composition effectively inhibiting differentiation of osteoclasts. A pharmaceutical composition including the peptide is bound with the RANKL and the peptide, instead of the RANK, thereby inhibiting the interaction between the RANKL and the RANK, and thus inhibiting osteoclast differentiation. | 12-18-2014 |
20140378377 | Methods for Detecting Cardiac Damage - The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient. | 12-25-2014 |
20150018273 | NOVEL COMPOSITIONS AND USES THEREOF - The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an RGD domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal. | 01-15-2015 |
20150057221 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L | 02-26-2015 |
20150119324 | METHODS OF DELIVERING PHARMACEUTICAL AGENTS - Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject. | 04-30-2015 |
20150133376 | EVALUATION OF CANCER DIAGNOSIS FOLLOWING CANCER RADIOTHERAPY AND POTENTIATION OF CANCER RADIOTHERAPY - A method for evaluation of cancer diagnosis following cancer radiotherapy, comprising: providing a serum sample of a cancer patient prior to the cancer radiotherapy; and measuring a leukemia inhibitory factor concentration in the serum sample. Also provided is a method for potentiation of cancer radiotherapy, comprising: administrating a leukemia inhibitory factor inhibitor or a leukemia inhibitory factor receptor inhibitor to a subject in need of the cancer radiotherapy. | 05-14-2015 |
20150133377 | One-Step Processing of Hydrogels for Mechanically Robust and Chemically Desired Features - The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials. | 05-14-2015 |
20150322414 | ANGIOPOIETIN-2 SPECIFIC TIE2 RECEPTOR - In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoietin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided. | 11-12-2015 |
20150335712 | Treatment of Diseases and Conditions Caused by Increased Vascular Permeability - The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). | 11-26-2015 |
20150343023 | METHODS FOR CARDIOPROTECTION AND CARDIOREGENERATION WITH DIMERS OF EGF FAMILY LIGANDS - The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue. | 12-03-2015 |
20150352185 | METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY - This invention is directed to methods and compositions for increasing the expression or activity of neprilysin in, for example, the frontal cortex or the entorhinal cortex using a progranulin polypeptide or effector. The present invention is further directed to methods of reducing microglia in the brain of a patient with neurodegenerative disease using a progranulin polypeptide or effector. | 12-10-2015 |
20150353618 | Methods and Pharmaceutical Composition for the Preservation of Vascular Endothelial Cell Barrier Integrity - The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction. | 12-10-2015 |
20150376252 | Norrin Mutant Polypeptides, Methods of Making and Uses Thereof - The present invention relates to Norrin mutant polypeptides that inhibit or reduce angiogenesis in various tissues. Methods for synthesizing recombinant Norrin and Norrin mutant polypeptides are provided. Methods of inhibiting or reducing aberrant angiogenesis comprise contacting a tissue undergoing aberrant angiogenesis with a composition comprising an isolated Norrin C mutant polypeptide. | 12-31-2015 |
20160000871 | TIE2 RECEPTOR ACTIVATION FOR GLAUCOMA - This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2− peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease. | 01-07-2016 |
20160009783 | OLIGOMERS FOR TNF SUPERFAMILY INHIBITION, METHODS OF MAKING AND USING | 01-14-2016 |
20160030454 | CANCER THERAPY - The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities. | 02-04-2016 |
20160045568 | CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA - The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment. | 02-18-2016 |
20160058907 | BIOMATERIAL COMPOSITIONS - Biomaterial compositions comprising organosilicon monomers (such as silorane monomers) and chemical curing systems or dual chemical/light curing systems, in conjunction with optional tetraoxaspiro[5.5]undecanes (“TOSUs”) and/or fillers. | 03-03-2016 |
20160060316 | TARGETING TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER WITH A HER3-TARGETING NANOPARTICLE - Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. | 03-03-2016 |
20160082084 | HEART FAILURE TREATMENT - The present invention relates to treating and/or preventing heart failure or one or more individual heart failure phenotypes in mammals using placental growth factor 2 (PlGF-2). | 03-24-2016 |
20160186188 | METHODS FOR ALTERING POLYPEPTIDE EXPRESSION AND SOLUBILITY - The invention is directed to methods and metric suitable for use in determining the solubility, expression and usability of a polypeptide encoded by a nucleic acid sequence. In certain aspects, the invention also relates to methods for introducing modifications in a polypeptide, for example through substitution of one or more codons in the nucleic acid sequence encoding the polypeptide, to increase or decrease the solubility, expression or usability of the polypeptide. | 06-30-2016 |